Spatial memory

Cornerstone Becomes End-to-End Learning Content Solution with Spatial Learning Acquisition

Retrieved on: 
Tuesday, March 19, 2024

Cornerstone OnDemand Inc. , a leader in learning and talent experience solutions, today announced the acquisition of extended reality capabilities and a team of highly specialized domain experts from Talespin, a spatial learning company focused on workforce skills development.

Key Points: 
  • Cornerstone OnDemand Inc. , a leader in learning and talent experience solutions, today announced the acquisition of extended reality capabilities and a team of highly specialized domain experts from Talespin, a spatial learning company focused on workforce skills development.
  • Talespin’s extended reality (XR) learning technology solidifies Cornerstone’s robust content subscriptions, curation, creation, and insights technology to create an end-to-end learning content solution powering the future of work.
  • A natural evolution from personalized is providing truly immersive learning experiences through spatial computing and GenAI.
  • This includes Talespin’s AI-powered, no-code XR content authoring tool, CoPilot Designer, and its generative AI immersive learning labs services offering.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.

The chickadee in the snowbank: A 'canary in the coal mine' for climate change in the Sierra Nevada mountains

Retrieved on: 
Thursday, January 4, 2024

As we reach the remote research site, I duck under a tarp and open a laptop.

Key Points: 
  • As we reach the remote research site, I duck under a tarp and open a laptop.
  • A chorus of identification numbers are shouted back and forth as fellow behavioral ecologist Vladimir Pravosudov and I program “smart” bird feeders for an upcoming experiment.
  • In recent history, intense winters are often followed by drought years here in the Sierra Nevada and in much of the U.S. West.
  • Our research shows that a mountain chickadee facing deep snow is, to borrow a cliche, like a canary in a coal mine – its survivability tells us about the challenges ahead.

The extraordinary memory of a chickadee

  • Cognition is the processes by which animals acquire, process, store and act on information from their environment.
  • Then, they use their specialized spatial memory to retrieve those food caches in the months to come.
  • We measure the spatial memory of chickadees using a classic associative learning task but in a very atypical location.
  • The setup allows us to measure the spatial memory performance of individual chickadees, because they have to remember which feeder their key enables them to open.

What’s the problem?

  • Harpold works to understand variations in climate patterns within forest environments, and one of his field sites lies alongside our chickadee research site.
  • The Sierra Nevada and other mountain ranges in western North America have been experiencing more extreme snow years and drought years, amplified by climate change.
  • In 2023’s record winter, over 17 feet (5 meters) of snow covered the landscape that our chickadees were using every day.

The cascading harms from too much snow

  • And if they do survive the winter, their nesting sites – tree cavities – may be buried under feet of snow in the spring.
  • Extreme snow oscillations also affect insects that are critical for feeding chickadee chicks.
  • Snow cover is good for overwintering insects in most cases, as it provides an insulating blanket that saves them from dying during those freezing months.
  • However, if the snow persists too long into the summer, insects can run out of energy and die before they can emerge, or emerge after chickadees really need them.
  • This leads to a decline in chickadee populations in years with worse whiplash – drought followed by high snow on repeat – especially at high elevations.

Lessons for the future

  • Our long-term research following these chickadees provides a unique window into the relationships between winter snow, chickadee populations and the biological community around them, such as coniferous forests and insect populations.
  • These relationships illustrate that climate change is a more complicated story than just the temperature climb – and that its whiplash and cascading effects can destabilize ecosystems.


Benjamin Sonnenberg receives funding from the National Science Foundation.

Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting

Retrieved on: 
Monday, April 24, 2023

SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of updated clinical data from its ongoing Phase I/II clinical trial of a single dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE). The data demonstrate >90% reduction in seizure frequency in the first and second patient at nine- and five-months post-treatment, respectively. In addition, neuropsychological testing suggests an improvement in memory in the first patient after NRTX-1001 administration. The data are being presented at the American Academy of Neurology (AAN) 2023 Annual Meeting which is being held April 22- 27 in Boston, MA and virtually.

Key Points: 
  • The data demonstrate >90% reduction in seizure frequency in the first and second patient at nine- and five-months post-treatment, respectively.
  • In addition, neuropsychological testing suggests an improvement in memory in the first patient after NRTX-1001 administration.
  • The data are being presented at the American Academy of Neurology (AAN) 2023 Annual Meeting which is being held April 22- 27 in Boston, MA and virtually.
  • NRTX-1001 interneurons are cryopreserved and shipped to clinical sites to be used as an allogeneic, off-the-shelf investigative therapy.

ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimer’s Disease

Retrieved on: 
Thursday, April 13, 2023

In the paper titled, “Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease,” the authors reviewed data associated with microglial pathways that have potential as drug targets for treatment of MCI and AD.

Key Points: 
  • In the paper titled, “Microglia: A pharmacological target for the treatment of age-related cognitive decline and Alzheimer’s disease,” the authors reviewed data associated with microglial pathways that have potential as drug targets for treatment of MCI and AD.
  • “It is encouraging to see the extensive research underway to identify potential drug targets.
  • We are proud of the original scientific contributions in this area by the inventors of ZyVersa’s Inflammasome ASC Inhibitor IC 100, Drs.
  • Robert W. Keane and Juan Pablo de Rivero Vaccari at the University of Miami Miller School of Medicine.” To review their latest publication on Alzheimer’s disease, Click Here .

Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Retrieved on: 
Tuesday, October 11, 2022

IHL-216A is Incannexs proprietary combination of cannabidiol (CBD) and isoflurane (ISO) that is being developed for treatment of TBI.

Key Points: 
  • IHL-216A is Incannexs proprietary combination of cannabidiol (CBD) and isoflurane (ISO) that is being developed for treatment of TBI.
  • Incannex submitted a pre-IND meeting package to the FDA in August 2022.
  • Chief Scientific Officer of Incannex, Dr. Mark Bleackley, said: Feedback from the FDA in the pre-IND meeting indicated that the agency is highly interested in the development of IHL-216A for treatment of traumatic brain injury.
  • IHL-216A has demonstrated neuroprotective activity in two separate animal models of traumatic brain injury, one representing moderate to severe injury and the other representing mild injury, or concussion.

AstaReal and University of Tsukuba, Japan awarded Patent on Astaxanthin and Exercise Therapy for Improving Cognitive Function

Retrieved on: 
Wednesday, December 1, 2021

AstaReal astaxanthin modulates genes in the brain that are involved in learning, memory and neuron formation.

Key Points: 
  • AstaReal astaxanthin modulates genes in the brain that are involved in learning, memory and neuron formation.
  • Exercise therapy has been shown to stimulate AHN, as well as enhance and help maintain cognitive function.
  • This new patent from AstaReal ( US 11,116732 ) shows that astaxanthin combined with exercise can improve the effects of exercise on AHN, learning, and spatial memory by modulating genetic expression in the hippocampus.
  • Pre -clinical studies led by Prof Hideaki Soya at the University of Tsukuba, showed Astaxanthin combined with exercise improved cognitive function better than either exercise or astaxanthin treatments alone.

Predicting Alzheimer's Disease-Like Memory Loss Before It Strikes

Retrieved on: 
Wednesday, November 20, 2019

By the time she begins to experience memory loss and other worrisome signs, cognitive decline has already set in.

Key Points: 
  • By the time she begins to experience memory loss and other worrisome signs, cognitive decline has already set in.
  • And decades of clinical trials have failed to produce treatments that could help her regain her memory.
  • As they age, ApoE4 mice often, but not always, develop signs of memory loss similar to those seen in people with Alzheimer's.
  • They found that mice with fewer SWRs and lower SG power were indeed more likely to have worse spatial memory deficits.